Beneficial cardiovascular actions of eplerenone in the spontaneously hypertensive rat

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 10, Issue 3, 2005, Pages 197-203

  Susic, Dinko ^a   Varagic, Jasmina ^a   Ahn, Jwari ^a   Matavelli, Luis C ^a   Frohlich, Edward D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Aldosterone; Coronary hemodynamics; Lisinopril; Myocardial fibrosis

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYPROLINE; LISINOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY HEMODYNAMICS; CORONARY VASCULAR RESISTANCE; DRUG POTENTIATION; HEART INDEX; HEART INJURY; HEART LEFT VENTRICLE MASS; HYPERTENSION; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT OUTCOME;

ANIMALS; BLOOD PRESSURE; CORONARY CIRCULATION; HYPERTENSION; LISINOPRIL; MALE; RATS; RATS, INBRED SHR; SPIRONOLACTONE; VASCULAR RESISTANCE;

EID: 25444516536     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840501000308     Document Type: Article

References (29)

1. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 83:1849-1865, 1991
2. Lijnen P. Petrov VV. Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. J Moll Cell Cardiol 31:949-970, 1999
3. Gonzales A, Lopez B, Diez J. Fibrosis in hypertensive heart disease: Role of the renin-angiotensin-aldosterone system. Med Clin North Am 88:83-97, 2004
4. Lacolley P, Safar ME, Lucet B, et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 37:662-667, 2001
5. Stockland JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol 284:H176-184, 2003
6. Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 15:164-169, 2002
7. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 34:1577-1584, 2002
8. Bravo EL. Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease. Curr Hypertens Rep 5:122-125, 2003
9. Weber KT, Gerling IC, Kiani MF, et al. Aldosteronism in cardiac failure: A proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets 4:505-516, 2003
10. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 17:1152-1156, 1997
11. Brown L, Duce B, Miric G, et al. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol 10(suppl 11):143-148, 1999
12. Young M, Funder JW. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 145:3153-3157, 2004
13. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cel Cardiol 25:563-575, 1993
14. Mazak I, Fiebler A, Muller DN, et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cell. Circulation 109:2792-2800, 2004
15. Fiebler A, Schmidt F, Muller DN, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor kappa-b activation in ungiotensin II-induced cardiac injury. Hypertension 37(part 2):787-793, 2001
16. Hao L, Kanno Y, Fukushima R, et al. Effects of eplerenone on heart and kidney in two-kidney, one-clip rats. Am J Nephrol 24:54-60, 2004
17. Trippodo N, Frohlich ED. Similarities of genetic (spontaneous) hypertension. Man and rat. Circ Res 48:309-319, 1981
18. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 69:107-115, 1991
19. Ishise S, Pegram B, Yamamoto Y, Kitamura Y, Frohlich ED. Reference sample microsphere method: Cardiac output and blood flows in conscious rat. Am J Physiol 239:H443-H449, 1980
20. Kaneko K, Susic D, Nunez E, Frohlich ED. Losartan reduces cardiac mass independent of pressure and coronary hemodynamic changes. J Hypertens 14:645-653, 1996
21. Susic D, Varagic J, Frohlich ED. Pharmacologic agents on cardiovascular mass, coronary dynamics, and collagen in aged spontaneously hypertensive rats. J Hypertens 17:1209-1215, 1999
22. Armitage P, Berry G. Statistical Methods in Medical Research. 3rd ed. Oxford: Blackwell Scientific Publications; 1994
23. Tanabe A, Naruse M, Hara Y, et al. Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. J Hypertens 22:1017-1023, 2004
24. Susic D, Nunez E, Hosoya K, Frohlich ED. Coronary hemodynamics in aging spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. J Hypertension 16:231-237, 1998
25. Kambara A, Holycross BJ, Wang P, et al. Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. J Cardiovasc Pharmacol 41:830-837, 2003
26. Varagic J, Susic D, Frohlich ED. Coronary hemodynamics and ventricular responses to angiotensin type 1 receptor inhibition: Interaction with angiotensin type 2 receptors. Hypertension 37:1399-1403, 2001
27. Varagic J, Susic D, Frohlich ED. Cilindipine improves coronary hemodynamics in spontaneously hypertensive rat without altering cardiovascular mass and collagen. J Hypertension 20:317-322, 2002
28. Martinez D, Rocha R, Matsumura M, et al. Cardiac damage prevention by eplerenone: Comparison with low sodium diet or potassium loading. Hypertension 39:614-216, 2002
29. Falkenstein E, Tillmann HC, Christ M, et al. Multiple actions of steroid hormones-A focus on rapid, nongenomic effects. Pharmacol Rev 52:513-555, 2000